InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,166.40
(
0.51%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,030.73
(
0.04%
)
Post# of 252185
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119839
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: maverick_1 post# 212687

Friday, 04/24/2020 12:50:08 PM

Friday, April 24, 2020 12:50:08 PM

Post# of 252185
MRK/AZN—Lynparza shows statsig-superior OS to hormonal agents (Xtandi, Zytiga) in the phase-3 PROFOUND study in second-line CRPC with certain genetic mutations:

https://www.businesswire.com/news/home/20200424005205/en

Lynparza is the only PARP inhibitor to show an OS benefit in this setting.

The PROFOUND study met its primary endpoint of radiographic PFS in Aug 2019, and the resulting NDA and MAA are currently under FDA and EMA review.

A trial of Lynparza in first-line CRPC is in progress with results expected in 2021.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up